

## Cancer Center of Boston

[View the current Cancer Center of Boston Page on BioPortfolio.com](http://www.bioportfolio.com)

(<http://www.bioportfolio.com/biocorporate/20391-Cancer+Center+of+Boston.html>)

### Contact Details:

**61 Lincoln St. Suite 307**

**Framingham**

**Massachusetts**

**01702**

**United States of America**

Tel: 617-739-6605

Fax: 617-739-4819

Email: [mbern@cancercenterofboston.com](mailto:mbern@cancercenterofboston.com)

The Cancer Center of Boston was established in September 1986 by Jacob J. Lokich, MD and Murray M. Bern, MD, formerly the chiefs of medical oncology and hematology, respectively, at the New England Deaconess Hospital. Their collaboration was based on the desire to develop a network of community based, freestanding facilities to diagnose and treat cancer and hematologic diseases with state-of-the-art therapies and access to clinical trials. Over the ensuing decade, the Boston facility has been expanded to include facilities or programs in Arlington (1987), Plymouth (1991) and Framingham (1994). In 2005, The Cancer Center relocated the Boston office to Chestnut Hill. Community based referrals are complemented by referrals from families and patients representing approximately 50% of all new patients. We see patients from regional, national and international locales, in part because of special areas of expertise such as infusion chemotherapy and participation on national and international clinical trial panels.

### Recent Publications by Cancer Center of Boston:



- [Same day Pegfilgrastim and CHOP chemotherapy for non-Hodgkin lymphoma.](#)  
*OBJECTIVES: To determine if "same day" Pegfilgrastim (Pf) with CHOP...*10th August, 2006  
The Cancer Center of Boston, Chestnut Hill, MA, USA.- *Am J Clin Oncol.* 2006 Aug;29(4):361-3. ([DOI](#) [Direct Link](#))
- [Same-day pegfilgrastim and chemotherapy.](#)  
*Pegylated filgrastim is a new formulation of a neutrophil...*7th January, 2006  
The Cancer Center of Boston in Boston, Plymouth, and Framingham,- *Cancer Invest.* 2005;23(7):573-6. ([DOI](#) [Direct Link](#))
- [Coagulopathy, following medical therapy, for carcinoma of the prostate.](#)  
*Cancer of the prostate can be associated with coagulopathy characterized...*8th October, 2005  
The Cancer Center of Boston, Boston, MA 02120, USA.- *Hematology.* 2005 Feb;10(1):65-8. ([DOI](#)

[Direct Link](#))

- [Treatment of factor XI inhibitor using recombinant activated factor VIIa.](#)  
*A 30-year-old female with severe factor XI deficiency of 0-2% acquired...*26th May, 2005  
The Cancer Center of Boston, The New England Baptist Hospital, Harvard- Haemophilia. 2005 Jan;11(1):20-5. ([DOI Direct Link](#))
- [Tumor response and survival end points in clinical trials: a clinician's perspective.](#)  
*Survival has become the gold standard for determining the relative...*29th April, 2005  
The Cancer Center of Boston, Boston, Massachusetts 02120, USA.- Am J Clin Oncol. 2004 Oct;27(5):494-6.
- [Observations on possible effects of daily vitamin K replacement, especially upon warfarin therapy.](#)  
*Daily parenteral vitamin K supplement is now recommended by the U.S. Food...*9th April, 2005  
Cancer Center of Boston, New England Baptist Hospital, Harvard Medical- JPEN J Parenter Enteral Nutr. 2004 Nov-Dec;28(6):388-98.
- [Capecitabine: fixed daily dose and continuous \(noncyclic\) dosing schedule.](#)  
*BACKGROUND: Oral fluoropyrimidines are presumed to emulate a parenteral...*30th December, 2004  
The Cancer Center of Boston, Boston, Massachusetts, USA.- Cancer Invest. 2004;22(5):713-7.
- [Cutaneous hand and foot toxicity associated with cancer chemotherapy.](#)  
*The purpose was to determine the optimal multifractionated (MF) dosing...*20th February, 2004  
The Cancer Center of Boston in Boston, Massachusetts 02120, USA.- Am J Clin Oncol. 2003 Oct;26(5):435-6. ([DOI Direct Link](#))
- [Alternating doublets: establishing the optimal multifractionated dosing schedule to administer docetaxel, cisplatin, gemcitabine, and vinorelbine in combination.](#)  
*The purpose was to determine the optimal multifractionated (MF) dosing...*5th February, 2004  
Cancer Center of Boston, 125 Parker Hill Ave., Boston, Plymouth, MA- Cancer Invest. 2003;21(6):830-6.
- [Very low dose warfarin as prophylaxis against ultrasound detected deep vein thrombosis following primary hip replacement.](#)  
*One mg daily warfarin was compared to variable dose warfarin (PT 1.3-1.5...*26th November, 2002  
The Cancer Center of Boston, Boston, Massachusetts, USA.- Am J Hematol. 2002 Oct;71(2):69-74. ([DOI Direct Link](#))

## Press Releases on Cancer Center of Boston:

<a href="#">AMA Honors Family Violence Prevention Expert</a>	7th November, 2009	American Medical Association	HOUSTON, Nov. 7 /PRNewswire-USNewswire/ -- The American Medical Association (AMA) proudly presented Lisa James, Director of Health at the Family Violence Prevention Fund, with the Citation for
<a href="#">AMA Has Chance to Rescind Support of HR 3962; AMA Shout-Out from Public Urges Doctors to Answer to PATIENTS Not AMA Leadership</a>	7th November, 2009	Association of American Physicians and Surgeons (AAPS)	HOUSTON, Nov. 7 /PRNewswire-USNewswire/ -- Members of the AMA are trying a last-minute tactic to introduce an emergency resolution rescinding the AMA's support of HR 3962. "We want to

<a href="#">PRSA Inducts Head of Public Relations for Kaiser Permanente Into the College of Fellows for Contributions to the Profession and Lifetime Achievement</a>	7th November, 2009 Kaiser Permanente	SAN DIEGO, Nov. 7 /PRNewswire/ -- The Public Relations Society of America (PRSA) will bestow the distinguished title of Fellow on Diane Gage Lofgren, senior vice president of Brand Strategy,
<a href="#">Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care</a>	7th November, 2009 CSL Behring	MIAMI BEACH, Fla., Nov. 7 /PRNewswire/ -- Patients reported C1-esterase inhibitor (C1-INH) concentrate is an effective therapy in treating acute swelling attacks at any body location for HAE, a rare
<a href="#">VA Summit Frames Plan to End Veteran Homelessness</a>	6th November, 2009 National Coalition for Homeless Veterans	WASHINGTON, Nov. 6 /PRNewswire-USNewswire/ -- The U.S. Department of Veterans Affairs held a historic three-day conference in the nation's capital to signal the beginning of a new mission for the

## BioNews Results for Cancer Center of Boston



- [Concert a benefit for cancer patients](#)  
*Portsmouth Herald: Nov 1 2009 7:54AM Matching: cancer center boston*
- [Carmel Pharma Introduces PhaSeal, Secondary Set \(C60\)](#)  
*Therapeutics Daily: Nov 1 2009 1:26PM Matching: cancer center boston*
- [Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular](#)  
*Journal of Clinical Oncology: Oct 31 2009 5:47PM Matching: cancer center boston*
- [Randomized Phase II Study of Gemcitabine Administered at a Fixed Dose Rate or in Combination With Cisplatin, D](#)  
*Journal of Clinical Oncology: Oct 31 2009 5:51PM Matching: cancer center boston*
- [American Society of Clinical Oncology 2009 Clinical Evidence Review on Radiofrequency Ablation of Hepatic Meta](#)  
*Journal of Clinical Oncology: Oct 31 2009 5:50PM Matching: cancer center boston*
- [Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recu](#)  
*Journal of Clinical Oncology: Oct 31 2009 5:49PM Matching: cancer center boston*
- [Local Excision Alone Without Irradiation for Ductal Carcinoma In Situ of the Breast: A Trial of the Eastern Co](#)  
*Journal of Clinical Oncology: Oct 31 2009 5:48PM Matching: cancer center boston*
- [Prospective Study of Prostate Tumor Angiogenesis and Cancer-Specific Mortality in the Health Professionals Fol](#)  
*Journal of Clinical Oncology: Oct 31 2009 5:51PM Matching: cancer center boston*

- [Histone Deacetylase Inhibitors in Cancer Therapy \[Review Articles\]](#)  
*Journal of Clinical Oncology: Oct 31 2009 5:48PM Matching: cancer center boston*
- [Clinical Dilemma of Ductal Carcinoma in Situ \[Editorials\]](#)  
*Journal of Clinical Oncology: Oct 31 2009 5:49PM Matching: cancer center boston*
- [Schering-Plough receives FDA complete response letter regarding PEGINTRON for malignant melanoma](#)  
*News-Medical.Net: Oct 31 2009 7:12AM Matching: cancer center boston*
- [Phase II Study of Cisplatin Plus Etoposide and Bevacizumab for Previously Untreated, Extensive-Stage Small-Cel](#)  
*Journal of Clinical Oncology: Oct 31 2009 5:52PM Matching: cancer center boston*
- [VMP \(Bortezomib, Melphalan, and Prednisone\) Is Active and Well Tolerated in Newly Diagnosed Patients With Mult](#)  
*Journal of Clinical Oncology: Oct 31 2009 5:51PM Matching: cancer center boston*
- [Researchers use BEZ235 drug to eliminate NSCL cancer](#)  
*News-Medical.Net: Oct 30 2009 6:40AM Matching: cancer center boston*
- [Theresa C. McCloud M.D., Travels to Argentina through International Education Program](#)  
*RSNA Link: Oct 30 2009 12:53AM Matching: cancer center boston*

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:  
Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road,  
Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

